Voyager Therapeutics, Inc. Stockholders Equity

• Voyager Therapeutics, Inc. showed a decrease of -34.6% in Stockholders Equity from 2024 to 2025.
• This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2015: -$47.14 million | Q1 2016: $163.60 million | Q2 2016: $155.70 million | Q3 2016: $149.12 million | Q1 2017: $122.70 million | Q2 2017: $105.29 million | Q3 2017: $85.21 million | Q1 2018: $98.29 million | Q2 2018: $81.97 million | Q3 2018: $65.59 million | Q1 2019: $100.69 million | Q2 2019: $118.40 million | Q3 2019: $108.16 million | Q1 2020: $79.76 million | Q2 2020: $76.88 million | Q3 2020: $166.24 million | Q1 2021: $136.21 million | Q2 2021: $110.54 million | Q3 2021: $87.42 million | Q1 2022: $75.93 million | Q2 2022: $60.05 million | Q3 2022: $79.82 million | Q1 2023: $216.96 million | Q2 2023: $199.03 million | Q3 2023: $176.22 million | Q1 2024: $340.89 million | Q2 2024: $335.42 million | Q3 2024: $330.31 million | Q1 2025: $272.70 million | Q2 2025: $243.94 million | Q3 2025: $219.83 million.
• Over the full 13 years of available data (2013 to 2025), Voyager Therapeutics, Inc.'s Stockholders Equity has grown by 5,215.6%.
• Historical annual values: Fiscal year 2025: $196.08 million | Fiscal year 2024: $299.76 million | Fiscal year 2023: $236.32 million | Fiscal year 2022: $59.02 million | Fiscal year 2021: $95.06 million | Fiscal year 2020: $154.32 million | Fiscal year 2019: $99.51 million | Fiscal year 2018: $46.45 million | Fiscal year 2017: $134.05 million | Fiscal year 2016: $135.92 million | Fiscal year 2015: $169.07 million | Fiscal year 2014: -$20.83 million | Fiscal year 2013: -$3.83 million.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026